Phenominer Database Results (83 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 70.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68198 829
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 14.0 d 1.06 5.5 in vivo visual assessment 0.0 0 70194 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 33.8 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69385 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 18.7 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 28 days 69418 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 20.0 d 8.5 in vivo visual assessment 0.0 0 69501 837
DA/ZtmKini inguinal lymph node wet weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. inguinal lymph node mass male 0 days 8 0.15 g/kg 0.01 0.02 post excision weight measurement 0.0 0 84928 1301
DA/ZtmKini plasma orosomucoid 1 level control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. orosomucoid 1 amount male 0 days 8 93.0 mg/l 8.13 23.0 radial immunodiffusion assay 0.0 0 84934 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 100.0 % in vivo visual assessment 0.0 0 84465 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait male 0 days 24 14.6 d 1.39 6.8 in vivo visual assessment 0.0 0 84467 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 14.9 d 1.52 5.9 in vivo visual assessment 0.0 0 84471 1301
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 13.0 d 1.8 5.09 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68197 829
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 14.9 d 1.03 3.4 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68133 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 16.2 d 0.92 2.6 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68707 839
DA/ZtmKini liver weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. liver mass male 0 days 8 28.96 g/kg 0.64 1.8 post excision weight measurement 0.0 0 84933 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67853 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 16.4 d 2.6 7.35 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68200 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68717 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 100.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68132 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68706 839
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103 days-131 days 10 3.5 % 1.49 4.7 body weighing method 0.0 intradermal injection 40 days from before p.i. 68708 839
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 15.8 d 1.9 8.9 in vivo visual assessment 0.0 0 69489 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 0 89.0 % 33.0 in vivo visual assessment 0.0 0 visual observation 69497 837
DA/ZtmKini ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63 days-150 days 20 0.0 % necropsy 0.0 intradermal injection 0 visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68125 838
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 19.7 d 2.48 8.6 in vivo visual assessment 0.0 0 69376 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 26.5 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 37 days 69380 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 23.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69411 892
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 15 93.0 % in vivo visual assessment 0.0 0 84469 1301
DA/ZtmKini spleen weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. spleen mass male 0 days 8 0.18 % 0.0 0.01 post excision weight measurement 0.0 0 84931 1301
DA/ZtmKini liver weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. liver mass male 0 days 8 32.73 g/kg 0.79 2.24 post excision weight measurement 0.0 0 84938 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67850 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 56.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68210 829
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 12.2 d 0.18 0.4 in vivo visual assessment 0.0 0 70196 1301
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103 days-131 days 10 2.8 % 1.26 4.0 body weighing method 0.0 intradermal injection 40 days from before p.i. 68716 839
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103 days-131 days 12 1.0 % 0.78 2.7 body weighing method 0.0 intradermal injection 40 days from before p.i. 68712 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69409 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 17 9.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69425 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 23 100.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68128 838
DA/ZtmKini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 50.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84515 1178
DA/ZtmKini thymus weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. thymus mass male 0 days 8 1.22 mg/g 0.1 0.29 post excision weight measurement 0.0 0 84937 1301
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 91.7 % in vivo visual assessment 0.0 0 84466 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 10 14.1 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 40 days 69410 892
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 81.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68225 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 6.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69386 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 0 15.6 d 9.4 in vivo visual assessment 0.0 0 69499 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 14 13.4 d 2.2 8.23 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68209 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 12 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68710 839
DA/ZtmKini plasma orosomucoid 1 level Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. orosomucoid 1 amount male 0 days 8 419.0 mg/l 82.02 232.0 radial immunodiffusion assay 0.0 0 84929 1301
DA/ZtmKini spleen weight to body weight ratio control condition Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. spleen mass male 0 days 8 0.17 % 0.0 0.01 post excision weight measurement 0.0 0 84936 1301
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 11 91.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68135 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 6 21.2 d 0.53 1.3 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68711 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 64.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days 69378 892
DA/ZtmKini body weight control condition Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. body mass female 56 days-77 days 0 162.9 g 9.5 body weighing method 0.0 0 68120 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 14 18.5 d 1.6 5.99 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68224 829
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65 days-112 days 22 19.6 d 2.22 10.4 in vivo visual assessment 0.0 0 69493 837
DA/ZtmKini ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63 days-150 days 23 61.0 % necropsy 0.0 intradermal injection 0 visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68129 838
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 100.0 % in vivo visual assessment 0.0 0 84470 1301
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 21 11.5 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69419 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 17 25.2 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 34 days 69424 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 16 50.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69384 892
DA/ZtmKini inguinal lymph node wet weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. inguinal lymph node mass male 0 days 8 0.68 g/kg 0.07 0.21 post excision weight measurement 0.0 0 84927 1301
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91 days-112 days 12 92.0 % in vivo visual assessment 0.0 0 68122 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 10 80.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67849 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67852 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63 days-105 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68201 829
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 5 100.0 % in vivo visual assessment 0.0 0 70192 1301
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 16.7 d in vivo visual assessment 0.0 subcutaneous injection 0 from 8 to 38 days 69391 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 14.3 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31 days days 69392 892
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103 days-131 days 11 14.4 % 2.47 8.2 body weighing method 0.0 intradermal injection 40 days from before p.i. CMO:0001400 68134 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68709 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68714 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91 days-112 days 22 82.0 % in vivo visual assessment 0.0 0 visual observation 69487 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63 days-150 days 20 60.0 % in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68124 838
DA/ZtmKini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 5 80.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84529 1178
DA/ZtmKini thymus weight to body weight ratio Freund's incomplete adjuvant (200 ul) (for 10 days) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. thymus mass male 0 days 8 0.6 mg/g 0.07 0.19 post excision weight measurement 0.0 0 84932 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait female 0 days 24 14.6 d 0.63 3.1 in vivo visual assessment 0.0 0 84468 1301
DA/ZtmKini post-insult time to onset of experimental arthritis Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 6 16.3 d 0.94 2.3 in vivo visual assessment 0.0 0 84472 1301
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 28 10.7 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days days 69381 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 94.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days 69390 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female 0 days 18 20.9 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days days 69393 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65 days-112 days 12 14.8 d 2.4 8.3 in vivo visual assessment 0.0 0 69491 837
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 6 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68713 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103 days-131 days 8 19.2 d 1.24 3.5 in vivo visual assessment 0.0 intradermal injection 0 from p.i. day 7 68715 839
DA/ZtmKini percentage of study population developing experimental arthritis during a period of time Freund's incomplete adjuvant (200 ul) Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96. joint integrity trait both 0 days 27 96.3 % in vivo visual assessment 0.0 0 70188 1301